Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Current Liabilities (2016 - 2025)

Fennec Pharmaceuticals filings provide 16 years of Total Current Liabilities readings, the most recent being $10.5 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 52.02% to $10.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.5 million, a 52.02% increase, with the full-year FY2025 number at $10.5 million, up 52.02% from a year prior.
  • Total Current Liabilities hit $10.5 million in Q4 2025 for Fennec Pharmaceuticals, up from $9.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $10.5 million in Q4 2025 to a low of $848000.0 in Q2 2021.
  • Median Total Current Liabilities over the past 5 years was $4.3 million (2022), compared with a mean of $5.4 million.
  • Biggest five-year swings in Total Current Liabilities: crashed 73.42% in 2021 and later soared 258.14% in 2022.
  • Fennec Pharmaceuticals' Total Current Liabilities stood at $1.7 million in 2021, then skyrocketed by 178.66% to $4.6 million in 2022, then skyrocketed by 63.88% to $7.6 million in 2023, then fell by 8.39% to $6.9 million in 2024, then soared by 52.02% to $10.5 million in 2025.
  • The last three reported values for Total Current Liabilities were $10.5 million (Q4 2025), $9.8 million (Q3 2025), and $8.4 million (Q2 2025) per Business Quant data.